Proteome and bioMerieux form stroke test pact
This article was originally published in Clinica
Proteome Sciences has licensed to bioMerieux its blood biomarkers for stroke, for use in the latter company's lab-based diagnostic tests. bioMerieux, based in Marcy l'Etoile, France, plans to assess the markers across a "well-defined sizeable patient population".
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.